anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The rationale for the proposed research comes from observations from a smaller study which demonstrated profound widespread symptom improvements in veterans with Gulf War Illness (GWI) after one month on the diet. Improvements were noted in every symptom domain and included significant reductions in overall symptom number (with an average of 9 symptoms going away), reduced pain, fatigue, depression, anxiety, and post-traumatic stress disorder (PTSD); and concurrent significant improvements in cognitive function and quality of life. Results also demonstrated that those who improved on the diet had a significant reduction in peripheral inflammation, as compared to those who did not improve on the diet. These benefits have been observed without any negative side effects and the majority of participants continued to follow the diet three months after study completion, suggesting continued improvement and good feasibility. The objectives of this study are: 1) to evaluate whether or not the substantial benefits observed in the recently completed clinical trial hold in a larger group of more diverse veterans with GWI, and 2) to identify blood and/or brain measures which predict improvement on the diet. By recruiting a large group of veterans which are representative of those with GWI, the findings of this research should be applicable to the larger GWI community. The impact of this research could be quite profound, with the diet being a no-risk, low-cost treatment option with no side effects, which allows each individual veteran to take back control of his/her health. There are no direct risks to following the diet since it is a healthy whole-food dietary approach which provides all necessary nutrients. The potential benefits of the diet include improvement in GWI symptoms; improvement in quality of life, potential for improvement in other health markers related to diet (such as obesity, diabetes, cardiovascular disease, high blood pressure) and the possibility of benefit to the larger community. If positive results are confirmed in the proposed study, then the next step would be to teach all Veterans Administration (VA) dietitians how to administer the low glutamate diet so that all veterans have access to it, which should be possible within 1-2 years of the completion of this study.
Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
PROBLEM TO BE SOLVED: To obtain an antioxidant which is a natural product, has strong oxidizing power and is not problematic in safety by using an extract of a plant of the genus Quararibea of the family Bombacaceae as the active ingredient. SOLUTION: This antioxidant contains an extract of a plant of the genus Quararibea of the family Bombacaceae as the active ingredient. Among the plants of the genus Quararibea of the family Bombacaceae, Zapote (scientific name: Quararibea amazonia) being a plant growing on e.g. a dry highland or a meadow in the Central or South America, especially at Andes is desirable. To obtain an extract, it is possible to use its flowers, fruits, leaves, stems, roots or the like or to use the whole body of the plant. The amount of the extract used is usually about 0.00001-10.0wt.% (in terms of the weight of the dry product). An extract obtained by extracting a plant of the genus Quararibea with a solvent such as water, a lower alcohol or chloroform is used as such or after being concentrated.
BACKGROUND: The drug resistance of carbapenem-resistant Acinetobacter baumannii bloodstream infections (CRAB-BSI), especially hospital-acquired infections, has promoted their rapid and vast spread. It is necessary to use reliable methods to establish better prediction models. According to Cox proportional hazards regression, a nomogram was established.
METHODS: A retrospective cohort study among patients who were diagnosed with CRAB-BSI was performed from January 2020 to December 2022. Univariate and multivariate Cox proportional hazards regression analyses were used to determine independent prognostic factors regarding CRAB-BSI. Then, nomograms were used to calculate the area under the curve (AUC), C-index, and calibration curve to determine the predictive accuracy and dis-criminability. Decision curve analysis (DCA) was employed to further confirm the clinical effectiveness of the nomogram.
RESULTS: A total of 98 cases were included in the comparison between the 28-day mortality group consisting of 32 patients and the 28-day survival group with 66 patients. The use of cefoperazone-sulbactam was significantly higher among patients who survived than among those who died. Univariable analysis revealed that factors such as primary diagnosis, time to inadequate antimicrobial therapy, and high serum creatinine and procalcitonin (PCT) levels were more prevalent in the mortality group. However, only primary diagnosis, time to inadequate antimicrobial therapy, and high PCT levels emerged as statistically significant risk factors for death in multivariate analysis and were used to construct the nomogram. The nomogram validation exhibited excellent performance.
CONCLUSIONS: The nomogram was sufficiently accurate to predict the risk and prognostic factors of CRAB-BSI, allowing for individualized clinical decisions for future clinical work. The cefoperazone-sulbactam did have an effect, but more studies are needed to interpret it.
BACKGROUND: Recently, there has been increasing interest in the possible role of the gut microbiota (GM) in the onset of migraine. Our aim was to verify whether bacterial populations associated with intestinal dysbiosis are found in pediatric patients with migraine. We looked for which metabolic pathways, these bacteria were involved and whether they might be associated with gut inflammation and increased intestinal permeability.
METHODS: Patients aged between 6 and 17 years were recruited. The GM profiling was performed by the 16S rRNA metataxonomics of faecal samples from 98 patients with migraine and 98 healthy subjects. Alpha and beta diversity analyses and multivariate and univariate analyses were applied to compare the gut microbiota profiles between the two group. To predict functional metabolic pathways, we used phylogenetic analysis of communities. The level of indican in urine was analyzed to investigate the presence of metabolic dysbiosis. To assess gut inflammation, increased intestinal permeability and the mucosal immune activation, we measured the plasmatic levels of lipopolysaccharide, occludin and IgA, respectively.
RESULTS: The α-diversity analysis revealed a significant increase of bacterial richness in the migraine group. The β-diversity analysis showed significant differences between the two groups indicating gut dysbiosis in patients with migraine. Thirty-seven metabolic pathways were increased in the migraine group, which includes changes in tryptophan and phenylalanine metabolism. The presence of metabolic dysbiosis was confirmed by the increased level of indican in urine. Increased levels of plasmatic occludin and IgA indicated the presence of intestinal permeability and mucosal immune activation. The plasmatic LPS levels showed a low intestinal inflammation in patients with migraine.
CONCLUSIONS: Pediatric patients with migraine present GM profiles different from healthy subjects, associated with metabolic pathways important in migraine.
Disclosed are novel tricyclic compounds of the formula (I) and the pharmaceutically acceptable salts thereof. Y is C or CH. When Y is C then Z is not present and the optional bond from Y to the C-11 carbon of the tricyclic nucleus is present. When Y is CH then Z  is present and Z is H or -OH. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula 1Ø Also disclosed are methods of treating cancer using the compounds of formula 1Ø
The utility model relates to a biologically-active composition, containing a biologically-active compound and poly-bacterial mixture, intended for use as an immune-stimulant and antioxidant. The immune stimulatory effect of the biologically-active composition is due to the bacterial mixture, which contains dead bacterial strains with maximally retained ability to activate the nonspecific and specific immune mechanisms of protection. The antioxidant effect of the biologically-active composition is a consequence of the specially developed combination (mineral-vitamin complex) of antioxidants, vitamins, and microelements, which affect different types of free radicals in the body. The antioxidant microelements are in the form of compounds with amino acids, and this form provides good stability in the digestive system and high intestinal absorption. The full range of all vitamins is provided, which together with the added chromium, reduce the risk from the harmfulness of the environment, irrational nutrition, chronic diseases, progression of age. The quantities satisfy or exceed the recommended daily intake of vitamins, but are considerably lower than the upper limits for riskless daily nutritional intake of vitamins. The biologically-active composition is intended for use as a nutrition supplement - for the prevention of and after conventional therapy of oncological diseases, in high risk patients with pre-cancer and patients in remission. It is harmless and can be taken for extended periods of time without side effects in people who are exposed to and working under conditions of chronic exposure to harmful factors of chemical, radiation, and biological nature, performing hard physical labor, active sportsmen.
Described herein are chimeric receptors. Chimeric receptors comprise a cytoplasmic domain; a transmembrane domain;  and an extracellular domain. In embodiments, the cytoplasmic domain comprises a cyptoplasmic portion of a receptor that when activated polarizes a macrophage. In further embodiments, a wild-type protein comprising the cytoplasmic portion does not comprise the extracellular domain of the chimeric receptor. In embodiments, the binding of a ligand to the extracellular domain of the chimeric receptor activates the intracellular portion of the chimeric receptor.  Activation of the intracellular portion of the chimeric receptor may polarize the macrophage into an M1 or M2 macrophage.
Methods are provided for predicting the effect of a drug given the drug dose and individual patient clinical characteristics. A neural network is trained on samples of clinical data including the observed drug dose and effect on patients, as well as their individual clinical characteristics. The neural network is then validated to ensure that its predictions fall within an acceptable error range. The neural network is used to predict the effect of a given drug dose for a given set of individual patient clinical characteristics. Methods are also provided for predicting the drug dose required to achieve a desired effect. Another neural network is trained on samples of clinical data including the observed drug dose and effect on patients, as well as their individual clinical characteristics. The neural network is then validated to ensure that its predictions fall within an acceptable error range. The neural network is used to predict the dose of a drug dose required to achieve a desired effect for a patient with a given set of individual clinical characteristics. The first neural network is used to generate training data for the second neural network.
The accurate identification of the parathyroid gland is a crucial aspect of thyroid and parathyroid surgery. Failing to recognize the parathyroid gland during thyroidectomy can result in the inadvertent removal of the gland, leading to postoperative hypocalcemia. On the other hand, during parathyroidectomy, there is a risk of mistaking other structures, such as lymph nodes, for parathyroid adenomas, which can leave the patient without a cure. Currently UAB employs intraoperative PTH or radioactive isotope techniques in conjunction with surgeon judgment. However, both methods have limitations, including being time-consuming, posing logistical challenges, and not providing feedback before gland removal.

Parathyroid fluorescence is a relatively new technology. It was initially discovered that the parathyroid gland emits fluorescence, which distinguishes it from the surrounding tissues. Additionally, indocyanine green dye is readily taken up by the parathyroid gland, making its detection easy to the naked eye. Research has demonstrated that parathyroid fluorescence, with or without indocyanine green, is not only safe but also helps reduce postoperative hypocalcemia and locate lesions in patients with imaging-negative parathyroid adenomas. However, the current use of parathyroid fluorescence is not standardized, and further studies are needed to explore its clinical utility in terms of cure rates and postoperative complications.
The invention provides walnut oil expelling wind and removing cold. The walnut oil expelling wind and removing cold comprises, by weight, 250-260 parts of East China wild walnut, 30-40 parts of linseed, 70-80 parts of zanthoxylum armatum, 50-60 parts of coconut shell, 60-100 parts of prepared rehmannia root, 30-40 parts of roasted sinapis seed, 50-70 parts of deer-horn glue, 20-30 parts of cinnamon, 20-30 parts of ephedra, 20-30 parts of ginger charcoal, 30-40 parts of raw liquorice and the like. In the preparation method, added zanthoxylum armatum has the functions of expelling wind and removing cold. Prepared rehmannia root nourishes yin blood, replenishes essence and nourishes bone marrow, when used in cooperation with deer-horn glue, prepared rehmannia root reinforces kidneys, supports yang and strengthens muscles and bones, and when prepared rehmannia root and deer-horn glue are combined and used, blood is nourished and yang is supported. Cinnamon and ginger charcoal are used for warming yang, expelling cold and promoting blood circulation, so that symptoms are treated. Ephedra is used for opening the grain of skin and the texture of the subcutaneous flesh, so that body surface congealing cold is expelled. Sinapis seed is used for eliminating phlegm, removing dampness and removing obstruction of qi and blood circulation and can remove phlegm inside the skin and outside the flesh. When sinapis seed and ephedra are used together, obstruction of qi and blood circulation is removed, and prepared rehmannia root and deer-horn glue achieve nourishment and will not cause stagnation. Raw liquorice achieves detoxification, moderates the property of the herbs and the like. The walnut oil can warm middle energizer to dispel cold and is suitable for being eaten by patients of rheumatism ostalgia, bone tuberculosis, chronic osteomyelitis, periostitis, chronic lymphadenitis, rheumatoid arthritis, thrombus-obliterated angiitis, muscle deep abscess and other diseases caused by blood deficiency and cold coagulation.
A JJ stent placed before retrograde intrarenal surgery (RIRS) may ease the procedure. However, it is important to note that a prolonged duration of double J stent (DJS) placement before RIRS may increase the risk of postoperative urinary tract infection (UTI). Various publications have established this association, although the duration of the DJS before surgery is scarce. Our study investigates the relationship between the pre-stenting period and postoperative UTI and establishes a cut-off period to minimize this risk. We included a total of 500 cases with preoperative DJS prior to RIRS. The patients were divided into five groups according to their preoperative stenting duration (Group 1: 0-15 days; Group 2: 16-30 days; Group 3: 31-45 days; Group 4: 46-60 days; Group 5: >60 days). Demographic and clinical data of the patients, stone properties, operation data, perioperative and postoperative complications (including fever and UTI), hospitalization time, and stone-free rates (SFR) were compared. The groups contained 53, 124, 102, 63, and 158 patients. The demographics of the patients in each group were similar. There was no statistically significant difference between DJS duration, perioperative/postoperative complications, and SFR, except for the ureteral access sheath (UAS) insertion rate. (p = 0.001). The postoperative fever/UTI rate was the lowest in Group 1 (p = 0.046) compared to other durations. Stent duration does not impact SFR. Longer stents enhance UAS insertion success but increase postoperative infection risk. Our results suggest that RIRS should be performed within two weeks, ideally 20 days following stent insertion, to minimize postoperative infection risk.
During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
A front-end system collects diagnostically relevant information or data, including pulse waveform information, and optionally timing information, symptom information, and/or diagnostic information. One or more sensors or transducers detect pulse waveforms in a consistent manner, across various subjects and practitioners. A back-end system stores diagnostically relevant information and diagnostic information, typically for a large population of subjects and practitioners. The back-end system generates system generated diagnoses and/or suggested remedial actions based on submitted inquiries or requests. The back-end system can advantageously employ machine learning techniques to identify correlations between defining characteristics or features of pulse waveforms and diagnoses, over a large number of samples submitted by a substantial number of practitioners, for instance of traditional Chinese medicine. The back-end system can also employ primary and/or secondary symptoms in identifying correlations.
This is a multicentric active surveillance prospective cohort study. The eligibility criteria defined are: low-risk prostate adenocarcinoma (clinical stage of cT1-T2a / Group Grade 1 (Gleason score less or equal to 6) / PSA less or equal to 10 ng/ml), transrectal prostate biopsy with at least 12 cores, estimated life expectancy over 10 years, clinical conditions for definitive treatment, multiparametric prostate MRI performed or planned.
Patients with arterial embolic disease have benefited greatly from antiplatelet therapy. However, hemorrhage risk of antiplatelet agents cannot be ignored. Herein, we describe the discovery of 2,3-dihydro[1,4]dioxino[2,3-g]benzofuran compounds as novel PAR4 antagonists. Notably, the isomers 36 and 37 with the chemotype of phenoxyl methylene substituted on the 2,3-dihydro-1,4-dioxine ring exhibited potent in vitro antiplatelet activity (IC50 = 26.13 nM for 36 and 14.26 nM for 37) and significantly improved metabolic stability in human liver microsomes (T1/2 = 97.6 min for 36 and 11.1 min for BMS-986120). 36 also displayed good oral PK profiles (mice: T1/2 = 7.32 h and F = 45.11%). Both of them showed overall potent ex vivo antiplatelet activity at concentrations of 6 and 12 mg/kg, with no impact on the coagulation system and low bleeding liability. Our work will facilitate development of novel PAR4 antagonists as a safer therapeutic option for arterial embolism.
The early and accurate identification of predictive biomarkers for antiviral treatment efficacy remains a significant clinical challenge, particularly in the management of chronic hepatitis B (CHB). This study aimed to assess whether the plasma metabolome could reliably predict the success of antiviral therapy in CHB patients. We conducted a retrospective analysis on 56 treatment-naive CHB patients at the First Affiliated Hospital of Zhejiang University from December 2013 to March 2016. Patients who underwent a 48-week treatment regimen of entecavir (ETV) and interferon-alpha (IFN-α) were randomly assigned to either a discovery cohort (n=29) or a validation cohort (n=27). Based on the outcome of the treatment, patients were classified as HBeAg seroconversion group (High responders, Hrp) or the non-remission group (Low responder, Lrp). Our methodology involved an untargeted analysis of the amine/phenol and carboxylic acid submetabolomes in the CHB patients under treatment, utilizing chemical isotope labeling (CIL) techniques with liquid chromatography-mass spectrometry (LC-MS). Several metabolites were identified as having significant diagnostic potential for distinguishing Hrp from Lrp, with areas under the receiver operating characteristic curve (AUC) exceeding those typical clinical indicators. Notably, four metabolites, namely 2-methyl-3-ketovaleric acid, 2-ketohexanoic acid, 6-oxo-1,4,5,6-tetrahydronicotinic acid, and α-ketoisovaleric acid, demonstrated exceptionally high sensitivity and specificity in both cohorts, nearing 100%. In contrast, the clinical indicators, including HBcAb, log(HBsAg), and HBeAb, demonstrated lower and inconsistent sensitivity and specificity between the discovery and validation cohorts. Using HBcAb as a marker, the sensitivity was 87.5% with 76.9% specificity in the discovery cohort; however, the sensitivity dropped to 46.7% with 91.7% specificity in the validation cohort. Using log(HBsAg), the sensitivity was 84.6% with 69.2% specificity in the discovery cohort, compared to 85.7% sensitivity and 83.3% specificity in the validation cohort. For HBeAb, the separation of Hrp and Lrp had a sensitivity of 87.5% with 69.2% specificity in the discovery cohort, while the validation cohort showed 86.7% sensitivity and 91.7% specificity.
The same 16 participants will be administered a single low dose (10 mg) of immediate-release oxycodone by mouth as a tablet. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 2 days will separate Arms 2 and 3.
Curcumin, a bioactive polyphenol derived from turmeric, has been reported to have anti-inflammatory properties. The current study investigated the anti-inflammatory effect of curcumin in the hippocampal subfields (CA1 and CA3) after exposure to cobalt (Co) and the impact of ERK protein. Twenty-eight albino Wistar rats were divided into four groups, each with seven randomly selected rats as follows: Control (distilled water), Cobalt (Co) only (40 mg/kg), 120 mg/kg or 240 mg/kg curcumin + Co (40 mg/kg). Treatment was via oral gavage for 28 days. We performed a biochemical investigation to determine the levels of proinflammatory cytokines (TNFα and IL-1β). Furthermore, we conducted an immunohistochemical evaluation to assess the expression of IBA1 by microglial cells and the immunoexpression of ERK protein in the hippocampus. Results revealed a significant (p<0.05) elevation in the tissue level of TNFα and IL-1β, an increase in the number of IBA1-positive microglia, and upregulation of ERK protein in the hippocampal subfields of the rats after exposure to cobalt-only. Nevertheless, pretreatment with curcumin restored these parameters to levels comparable to control. In conclusion, our results showed that curcumin abrogated the Co-induced neuroinflammation by suppressing the release of proinflammatory biomarkers, reducing microgliosis, and modulating the ERK/MAPK pathway.